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Pediatric acute myeloid leukemia (AML) is a heterogeneous disease and remains clinically challenging. Currently
chemotherapies are frequently associated with treatment-related death and long-term side effects. Therefore,
alternative approaches with lower toxicity are highly desired. Ginsenosides and metabolites are the main
ingredients responsible for the multiple pharmaceutical functions of ginseng, which is one of the most commonly
consumed herbal medicines world widely. In the present study, we demonstrated that compound K, a major
ginsenoside metabolite, inhibited the growth of the clinically relevant pediatric AML cell lines in a time- and
dose-dependent manner. This growth inhibitory effect was attributable to suppression of DNA synthesis during cell
proliferation. Furthermore, we observed significant G1 cell cycle arrest and apoptosis induced by compound K. The
induction of apoptosis was accompanied by DNA double strand breaks. Our findings suggest that as a low toxic
natural reagent, compound K could be a potential drug for pediatric AML intervention and to improve the
outcome of pediatric AML treatment.
Keywords: Ginsenoside, Compound K, Pediatric acute myeloid leukemiaIntroduction
Pediatric acute myeloid leukemia (AML) remains a
therapeutically challenging disease, which accounts for
15-20% of all childhood acute leukemia but is responsible
for more than half of disease-specific deaths in these pa-
tients [1]. The treatment and the patient supportive care
have improved significantly over the past decades,
resulting in long-term survival in up to 65% of children
with AML [2]. However, current chemotherapy is associ-
ated with high frequency of treatment related deaths and
long-term side effects [3-5]. In addition, 20-40% patients
do not respond to chemotherapy initially, while in those
responsive patients, approximately 50% diseases will
eventually relapse [2,6]. Therefore, new therapies for
pediatric AML patients are urgently needed, especially
for those with primary refractory or relapsed diseases.
Ginseng root is one of the most commonly used herbal
medicines in the United States and East Asia for its
multi-pharmaceutical functions [7-9]. Intake of ginseng
root was reported to associate with reduced risk of vari-
ous types of cancer in a case–control study conducted in* Correspondence: yanchen2012@126.com
Department of Hematology, Xiangya Hospital, Central South University,
Changsha, Hunan 410008, P.R. China
© 2013 Chen et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orKorea [10]. Ginsenosides are considered the main active
ingredients responsible for the pharmaceutical activities
of ginseng root [11]. Ginsenosides belong to a family of
steroidal saponins and the two major groups of gin-
senosides include protopanaxadiol and protopanaxatriol
[12]. Orally taken ginseng products are usually not
decomposed by gastric juice or liver enzymes before getting
into the large intestine, where ginsenosides are metabolized
by bacteria through deglycolation [12]. This process cleaves
the sugar moieties of the ginsenosides in a stepwise manner
to produce intermediate metabolites and finally pro-
topanaxadiol-aglycone and protopanaxatriol-aglycone from
protopanaxadiol group and protopanaxatriol group, re-
spectively [12].
Several ginsenosides have been reported to exert anti-
cancer effects ascribed to their ability to inhibit DNA
synthesis, angiogenesis and invasion, as well as induce
cell cycle arrest and apoptosis [8]. For leukemia, gin-
senoside Rh1 showed suppressive effect on MAPK sig-
naling pathway, resulting inhibition of invasion and
migration of THP-1 acute monocytic cells [13]. Another
major intestinal ginsenoside metabolite compound K
(structure shown in Figure 1) was shown to induce apop-
tosis through caspases-mediated pathways in HL-60td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and




Figure 1 Structure of Rd, Rg3 and compound K.
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we describe a series of experiments designed to test the
effect of compound K on pediatric acute myeloid leu-
kemia cell lines and provide rationale for development of
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Figure 2 Inhibitory effect of PPD on the growth of pediatric AML cell
by SRB assay following treatment with 5, 10 or 20 μM compound K for indMaterials and methods
Cell lines and reagents
The pediatric AML cell lines Kasumi-1 and MV4-11 were
purchased from American Type Culture Collection
(Manassas, VA). The cells were cultured in RPMI 1640
supplemented with 10% fetal bovine serum (FBS), plus
2 mML-glutamine, 100 U/ml penicillin and 100 μg/ml
streptomycin (Invitrogen). Compound K (99%) was pur-
chased from the National Institute for the Control of
Pharmaceutical and Biological Products (NICPBP, Beijing,
China). All experiments were performed with the ap-
proved of the Central South University Institutional Care
and Use Committee (IACUC).
Cell viability assay
Cell viability was determined using the Sulforhodamine
B (SRB) method as described [16]. Briefly, at the point of
sample collection, the cells cultured in 96-well plates
were fixed in 10% trichloroacetic acid (TCA) and incu-
bated for 3 hr at 4°C. The fixed cells were washed with
tap water for 4 times followed by staining with 0.4% SRB
(Fluka) for 30 min at room temperature. The excess dye
was washed off with 1% acetic acid for 4 times and the
cells were dried by blow dryer. 150 μl 10 mM Tris-base
(pH10.5) was added to each well to solubilize SRB by
shaking the plates for 5 min on a shaker and the absorb-
ance of SRB was measured at 550 nm.
Cell proliferation assay
The cell proliferation was assayed based on the measure-
ment of 5-bromo-2-deoxyuridine (BrdU) incorporated
into cellular DNA during cell proliferation process by
using the Cell Proliferation ELISA BrdU Kit (Roche Ap-
plied Science) as per manufacturer’s protocol. In brief, the
BrdU labeling solution was added at the final concentra-
tion of 10 μM to the cell culture in 96-well plates during
the last 4 hr of compound K treatment. After removal of
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lines Kasumi-1 (A) and MV4-11 (B). The cell viability was assessed









0 6 12 20









Figure 3 Suppression of proliferation by compound K in
Kasumi-1 cells. Cell proliferation following treatment with 20 μM
compound K for indicated duration was quantified by using
colorimetric immunoassay based on measuring BrdU incorporation
during DNA synthesis. Bar: SEM. *: p < 0.05 from untreated control.
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FixDenat solution was flicked off and the cells were incu-
bated with anti-BrdU-POD solution for 90 min at room
temperature. The cells were then washed with PBS for
3 times and incubated with Substrate solution for 15 min
at room temperature, and the absorbance was measured
at 405 nm (reference wavelength at 490 nm).
Cell cycle analysis
Cells treated with compound K at indicated duration were
trypsinized and fixed in 70% ethanol for ≥2 hr on ice.
After a brief centrifugation, the cell pellet was suspended
in propidium iodide staining solution containing 0.1%
(v/v) Triton X-100, 0.2 mg/ml DNase-free RNase A, and
20 μg/ml propidium iodide. After incubation at room
temperature for 30 min, cells were analyzed for DNA con-
tent by flow cytometry.
Cell apoptosis assay
Cell apoptosis was detected based on assessing cytoplasmic
histone-associated DNA fragments by using the Cell Death
Detection ELISAPLUS Kit (Roche Applied Science) as per
manufacturer’s instruction. In brief, at the point of sam-
ple collection, detached cells in 96-well plates were precipi-
tated by centrifugation and pooled with attached cells.Table 1 Compound K induces G1 cell cycle arrest of
Kasumi-1
G1 S G2
0 hr 74.58 ± 1.38 17.49 ± 1.66 9.48 ± 0.29
6 hr 72.24 ± 2.54 18.29 ± 1.58 9.90 ± 0.86
12 hr 79.15 ± 1.12* 11.56 ± 0.36* 9.15 ± 0.63
20 hr 83.25 ± 1.69* 8.36 ± 0.74* 8.80 ± 0.87
Induction of G1 cell cycle arrest by compound K in Kasumi-1 cells. Cell cycle
distribution was determined by flow cytometry analysis. Data represent % of
cells at different cell cycle phases. *: p < 0.05 from untreated control.Supernatant containing cytoplasmic fraction was trans-
ferred to the streptavidin-coated plate. Immunoreagent
was then added to each well in the plate and incubated on
a shaker for 2 hr at room temperature. The solution was
removed and the plate was washed with incubation buffer
for 3 times, followed by ABTS solution incubation until
sufficient color was developed. The reaction was stopped
by addition of ABTS Stop Solution and the absorbance
was measured at 405 nm (reference wavelength at
492 nm).Western blotting
Soluble protein extracts or immunoprecipitated protein
were boiled in sample buffer and subjected to SDS-
polyacrylamide gel electrophoresis. Separated protein bands
were electrophoretically transferred to polyvinylidene
difluoride (PVDF) membrane (Thermal Fisher Inc.). Pri-
mary antibodies used were γH2AX, cleaved PARP, cleaved
caspase-3 (Cell Signaling Technology, Cat. 9718, 5625
and 9664, respectively), and β–actin (Santa Cruz, sc-
47778). The intensity of immunoreactive protein bands
was measured using the Odyssey Infrared Imaging Sys-
tem (Li-Cor).Statistical analysis
Data are presented as the mean ± SEM from three inde-
pendent experiments. The Student’s two-tailed t test
was used to determine the difference between treatment
group and control group.Results
Compound K inhibits growth and proliferation of
pediatric AML cells
We first examined the effect of compound K on the
growth of Kasumi-1 and MV4-11 cells using the SRB
assay as described in Materials and Methods. As
presented in Figure 2A and 2B, the cells were treated
with 5, 10 or 20 μM compound K for indicated time and
compound K showed significant growth inhibition in a
dose- and time-dependent manner in both cell lines. We
then assessed the effect of compound K on Kasumi-1
cell proliferation as determined by DNA synthesis using
the Cell Proliferation ELISA BrdU Kit. We found that
the BrdU incorporation was significantly suppressed at
12 hr by 20 μM compound K, and this suppression be-
came more dramatic at 20 hr of treatment (Figure 3).
Notably, the inhibition of proliferation at 20 hr was
already ~65%, while the inhibition of growth at 24 hr
was only ~30%, indicating that the effect of compound
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Figure 4 Induction of apoptosis by compound K in Kasumi-1 cells. A. Cell apoptosis following treatment with 20 μM compound K for
indicated duration was quantified by using photometric enzyme-immunoassay based on measuring cytoplasmic histone-associated-DNA-
fragmentation. Column: fold of induced apoptosis index compared to untreated control. Bar: SEM. *: p < 0.05. B & C. Western blot analysis of
γH2AX, cleaved PARP and cleaved caspase-3. Kasumi-1 cells were treated with different doses of compound K as indicated for 20 hr and then
subjected to Western blot analysis.
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pediatric AML cells
In order to further demonstrate the effects of compound
K on earlier cellular events, we then evaluated Kasumi-1
cell cycle distribution upon compound K treatment. The
cells were treated with 20 μM compound K for indicated
duration and then processed and subjected to flow cytom-
etry analysis. The percentage of DNA content at different
cell cycle phases was presented in Table 1, showing that
starting from 12 hr of compound K treatment, significant
G1 arrest was observed. The effect continued to escalate
with time. We next examined the effect of compound K
on apoptosis in Kasumi-1 cells by using the Cell Death
Detection ELISAPLUS Kit that quantitatively determines
cytoplasmic histone-associated DNA fragments inducedby cell death. We found that compound K induced signifi-
cant apoptosis at 12 hr of treatment and this induction
became more evident at 20 hr (Figure 4A). Compound
K-induced apoptosis was further validated by Western
blotting analysis of γH2AX, the phosphorylated form of
H2AX as the cellular response to DNA double strand
breaks [17]. As shown in Figure 4B, compound K treat-
ment led to increased expression of γH2AX in a
dose-dependent manner. In support of this finding, the
expression of cleaved PARP and caspase-3 was also signifi-
cantly elevated in response to compound K treatment
(Figure 4C), suggesting compound K-induced DNA
double strand breaks triggered apoptosis. This is consis-
tent with our cell growth inhibition result. Taken together,
these observations suggest that the growth inhibitory
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attributable to suppression of cell proliferation and induc-
tion of G1 cell cycle arrest and apoptosis.
Discussion
Improvements in supportive care, including the use of
antibiotics, antifungal treatment, matched related in bone
marrow transplantation, increased days of conventional
induction chemotherapy, have contributed significantly to
the prolonged survival of patients with pediatric acute mye-
loid leukemia (AML) [2,3]. However, further intensification
of antileukemia therapies may cause treatment-related
long-term side effects and mortality [2,3]. Therefore, it is
imperative to develop novel approaches with lower
toxicity to improve the outcome of pediatric AML
treatment.
The use of ginseng has been documented for centuries
in the Far East, especially in China and Korea, for im-
proving physical vitality and curing diseases [18]. Now-
adays, ginseng and its products are among the most
commonly consumed herbal medicines as a tonic for en-
hancing well-being and also as a complementary therapy
for cancer intervention in many countries [7]. Common
side effects caused by overdose of ginseng include inabi-
lity to sleep, nausea, diarrhea, epistaxis, high blood pres-
sure and headache [19]. However, ginseng is very well
tolerated by most people and considered nontoxic at high
dose to the animals tested, making it an attractive candi-
date for disease intervention [20].
As the main ingredients, over 100 ginsenosides have
been identified and some of them have been tested in
several cancer models including leukemia [21]. Interes-
tingly, it appears that the sugar chain complex is inversely
associated with the anti-cancer effect of ginsenosides [12].
The proposed mechanism mediating this inverse associ-
ation is that ginsenosides with less sugar moieties have in-
creased hydrophobic character, which lead to increased
permeability of cell membrane and therefore the uptake of
compounds [22]. As a major intermediate metabolite of
ginsenosides, compound K has relatively short side chain
compared with its precursors (Figure 1) [12], and has been
shown to induce apoptosis in human leukemia cells [14]. In
the present study, we demonstrated for the first time the
anti-cancer effect of compound K in a clinically relevant
cell line, Kasumi-1 [23]. In addition to cell growth inhib-
ition, compound K suppresses cell DNA synthesis and in-
duces cell cycle arrest at G1 phase. Furthermore, we
showed that compound K was able to induce DNA double
strand breaks associated with apoptosis. Our findings sug-
gest that as a natural existing, low toxicity reagent, com-
pound K is a potential approach for pediatric AML therapy.
Future study may focus on combination of compound K
with conventional chemotherapies to lower the dose and
improve the outcome of pediatric AML treatment.Competing interests
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